Ventricular Assist Device (VAD) Market Sustained by Rising Heart Failure Cases
Global Ventricular Assist Device (VAD) Market Sustained by Rising Heart Failure Cases
November 28, 2025 – The global market for Ventricular Assist Devices (VADs), also known as heart pumps, is experiencing steady growth as the world grapples with a rising tide of cardiovascular disease (CVD) and severe heart failure. VADs are critical mechanical circulatory support devices that help the failing heart pump blood.
Market Size and Growth Projections
The VAD market, which includes both Implantable Heart Pumps (for chronic failure) and Percutaneous Catheter-Based Heart Pumps (for acute failure), is estimated to be valued between $2.2 billion and $3.8 billion USD in 2025. Analysts project a Compound Annual Growth Rate (CAGR) of 5% to 10% through 2030.
Driving Force: The Global Burden of CVD
Cardiovascular disease is the world’s leading killer, causing nearly 1 in 3 global deaths (an estimated 20 million deaths in 2021). The number of people living with CVD is around 640 million and is projected to continue rising due to aging populations and changing lifestyles.
VADs offer critical support for patients with acute cardiogenic shock (post-heart attack/surgery, myocarditis) and provide a life-saving therapy for those with severe, end-stage chronic heart failure. Heart recovery, enabled by VAD support, is often a preferred clinical outcome due to lower overall long-term healthcare costs.
Competitive Landscape: Global Leaders and Chinese Challengers
The VAD market is currently dominated by two global medical giants, holding a market share exceeding 90%.
| Global Leader | Key Product/Acquisition | VAD Type |
| Abbott | HeartMate 3 (Magnetic Levitation LVAD) | Implantable Heart Pump |
| Johnson & Johnson | Acquired Abiomed (Impella® Series) in 2022 | Percutaneous Catheter-Based Heart Pump |
Notably, Medtronic ceased distribution and sales of its HVAD™ System in June 2021, prompting a transition to alternative commercially available devices.
Rise of Chinese Innovators
While having a shorter history in the VAD market, Chinese firms are rapidly gaining ground, supported by national initiatives to promote domestic medical device production (localization).
| Chinese Company | Core Product | Key Achievement |
| Shenzhen Core Medical | Corheart®6 (LVAD); CorVad®4.0/6.0 (PVA System) | Corheart®6 is the world's smallest and lightest commercialized magnetic levitation implanted heart pump (approved 2023). CorVad® is expected to be China's first approved percutaneous VAD (2026). |
| Chongqing Evaheart | EVAHEART®Ⅰ | China's first approved implanted Left Ventricular Assist System (2019). |
| Suzhou Tongxin | CiFu®VAD (Magnetic Levitation LVAD) | Approved by China's NMPA in November 2021. |
| RocketHeart Technology | HeartCon® (Magnetic-hydrodynamic Bearing LVAD) | Approved by China's NMPA in July 2022. |
Shenzhen Core Medical, for instance, has seen its revenue surge from $2 million USD in 2023 to an estimated $20 million USD in 2025.
Geographical Market Breakdown
The market is concentrated geographically, with North America being the largest market, followed by Europe and Asia Pacific. The United States alone accounts for over 90% of the North American market, with Japan and China being the two largest markets within the Asia Pacific region.